ClinicalTrials.gg

Program

BI 764524

A development code.

In Boehringer Ingelheim's pipeline, Sema3A antibody. Its studies are mostly in Diabetic Retinopathy, led by Boehringer Ingelheim.

Furthest: phase 2, since Jun 8, 20202 company-led studies, 1 open or runningNext primary completion: Mar 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim21 open or runningphase 2since Jun 8, 2020Jun 8, 2020Mar 5, 2027phase 2 · NCT06321302
  • Named in Boehringer Ingelheim’s own pipeline as BI 764524, phase 2, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 8, 2020First study: phase 2 study in Diabetic RetinopathyFirst studyNCT04424290 · 45 enrolled · United States, United Kingdom
  2. Mar 14, 2024Phase 2 study in Diabetic RetinopathyNCT06321302 · 175 planned · United States, Germany, Hungary and more

Ahead

  1. Mar 5, 2027Primary completion: phase 2 study in Diabetic RetinopathyNCT06321302

TargetBeta

“Sema3A antibody”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06321302Diabetic Retinopathy · United States, Germany, Hungary and more2RecruitingMar 5, 2027175
NCT04424290Diabetic Retinopathy · United States, United Kingdom2CompletedApr 28, 202345

How it is read

Names in the registry

  • “BI 764524”, 2 entries

Codes read as this program: BI764524.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.